---
format:
  revealjs:
    spotlight: true
    touch: true
    controls: true
    pointer: true
    center-title-slide: false
    transition: fade
    transition-speed: fast
    scrollable: true
    slide-number: true
    incremental: false
    multiplex: true
    chalkboard: true
    theme: [custom.scss]
    filters:
     - highlight-text
bibliography: references.bib
lightbox: true
csl: diagnostic-microbiology-and-infectious-disease.csl
revealjs-plugins:
  - pointer
---

## Posaconazole therapeutic drug monitoring: <br>Where do we stand? {background-image="images/bloodsample.jpg" background-opacity="0.2"}

<br> <br> <br> <br>

**Russell E. Lewis**, **Pharm.D., FCCP** <br> Associate Professor of Infectious Diseases <br> Department of Molecular Medicine <br> University of Padua <br> <br>

![](images/University_of_Padua_seal.svg){width="125"}

## Disclosures {background-image="images/bloodsample.jpg" background-opacity="0.2"}

<br>

-   **Royalities:** UptoDate

-   **Research support:** Gilead Inc.

-   **Speaking:** Avir, Gilead, F2G, Pfizer

-   **Advisory:** Gilead, F2G, Synexis, Basilea, Cidara

::: aside
Last 5 years
:::

## Timeline of posaconazole TDM {.smaller}

```{mermaid}
%%{init: {
    'theme': 'base',
    'themeVariables': {
      'fontFamily': "Arial, sans-serif",
      'fontSize': '28px',
      'primaryColor': '#cfe2f3',
      'primaryTextColor': '#000000',
      'primaryBorderColor': '##ffffff',
      'lineColor': '#000000',
      'secondaryColor': '#d9ead3',
      'tertiaryColor': '#fce5cd'
    }
  }
}%%


timeline
section Suspension era- <br>TDM essential for all patients
  2006: Suspension formulation approved by the FDA, EMA
  2007: Prophylaxis and refractory IA data: Cornely et al. NEJM: Ullmann et al. NEJM: Walsh et al. CID 
  2010: TDM targets- Prophylaxis > 700 ng/mL treatment: Jang et al. CP&T 
  2012: "Real-life" validation of TDM targets: Dolton et al. AAC: Many other single-centre studies
section New formulations- <br> TDM still essential?
  2013: FDA approval of posaconazole ER tablets 
  2015: FDA approval of posaconazole IV formulation: Cornely et al. JAC
  2021: Phase III treatment data: Maertens et al. Lancet 
  2023: No observed ER relationship: Maertens et al. Clin Drug Investig
section Targeted TDM- <br> which patients?
  2025: Extreme variablity in ICU : Single centre studies : Roberts et al. <br> SAFE-ICU <br> Inten Care Med
  
```

::: aside
[@cornely2007; @ullmann2007; @walsh2007; @jang2010; @cornely2017; @maertens2021; @maertens2023; @roberts2025]
:::

# Case #1: Posaconazole prophylaxis post HSCT

<br>

-   56 year-old female patient with AML undergoing haploidentical HSCT with BuFLU conditioning

-   **Prophylaxis:**

    -   Micafungin 50 mg/day starting at neutropenia onset until completion of post-stem cell infusion Cy on Day+5

    -   Posaconazole 300 mg BID day followed by 300 mg daily.

    -   On day +10 of transplant when patient has ANC 0.1, a posaconazole trough conncetration is ordered

    -   Result= 450 ng/mL

## References